Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Brolucizumab Action Pathway
Homo sapiens
Drug Action Pathway
Brolucizumab, also known as RTH258 or ESBA1008, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration. It functions as a vascular endothelial growth factor (VEGF) inhibitor, specifically targeting major VEGF-A isoforms (VEGF110, VEGF121, and VEGF165). By inhibiting these isoforms, brolucizumab reduces the proliferation of endothelial cells, vascularization of tissue, and permeability of blood vessels, which are processes associated with neovascular AMD. It has a relatively long duration of action, typically administered on a monthly basis. Patients should be informed about potential risks, including endophthalmitis, retinal detachment, and arterial thromboembolic events, associated with this medication.
References
Brolucizumab Pathway References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Perrot-Applanat M: VEGF isoforms. Cell Adh Migr. 2012 Nov-Dec;6(6):526-7. doi: 10.4161/cam.23256. Epub 2012 Nov 1
Tabrizi MA, Tseng CM, Roskos LK: Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006 Jan;11(1-2):81-8. doi: 10.1016/S1359-6446(05)03638-X
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Settings